SCHEMBL3827482

SCHEMBL3827482

NC(=O)c1sc(-c2cccnc2)nc1Nc1ccccc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.54
CYP3A4 P08684 4/20 0.54
CYP2C19 P33261 3/20 0.54
LMNA P02545 1/20 0.54
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
MAPT P10636 2/20 0.46
MAPK8 P45983 1/20 0.43
MAPK10 P53779 1/20 0.43
RAB9A P51151 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CDC7 O00311 4/20 0.42
DBF4 Q9UBU7 3/20 0.42
CCNE1 P24864 2/20 0.42
CDK2 P24941 2/20 0.42
ROCK2 O75116 1/20 0.41
MAP4K4 O95819 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41
CDK7 P50613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3831608 0.81 IKBKB (0.50) MAPTMAPK8MAPK10RAB9AP2RY1
SCHEMBL3830680 0.78 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19LMNAMEN1
SCHEMBL3831402 0.74 IRAK4 (0.54) CYP1A2CYP3A4CYP2C19LMNAMEN1
SCHEMBL3842362 0.72 GAA (0.47) LMNAMEN1KMT2AMAPTRAB9A
SCHEMBL3825251 0.71 RXFP1 (0.46) MEN1KMT2AMAPTMAPK8MAPK10
SCHEMBL13674671 0.71 SMN1; SMN2 (0.47) MAPTRAB9AALDH1A1P2RY1
SCHEMBL5211666 0.71 CYP1A2 (1.00) CYP1A2CYP3A4CYP2C19LMNAMEN1
SCHEMBL15626275 0.71 CYP1A2 (0.71) CYP1A2CYP3A4CYP2C19LMNAMEN1
SCHEMBL3843773 0.71 RAB9A (0.45) LMNAMAPTMAPK8MAPK10RAB9A
SCHEMBL3828117 0.69 CYP1A2 (0.53) CYP1A2CYP3A4CYP2C19LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270456-A1 Novel chemical compounds HASEGAWA MASAICHI 2009-10-29 US claimed
US-20090270456-A1 Novel chemical compounds HASEGAWA MASAICHI 2009-10-29 US disclosed
US-20090270456-A1 Novel chemical compounds HASEGAWA MASAICHI 2009-10-29 US disclosed
US-20090270456-A1 Novel chemical compounds HASEGAWA MASAICHI 2009-10-29 US disclosed
EP-1718297-A4 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-09-02 EP disclosed
EP-1718297-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-08 EP disclosed
WO-2005070042-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270456-A1 Novel chemical compounds HIPK3, HIPK2, HIPK1 CYP1A2 4691/4885CYP3A4 4832/4885CYP2C19 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.